At the American Society of Clinical Oncology virtual annual meeting last week, some firms presented data on different techniques to analyze a patient’s blood sample for epigenetic modifications, in particular DNA methylation, in their circulating tumor DNA, or ctDNA. Read more . . .
As the clinical applications for liquid biopsy testing begin to widen in the cancer space, biotech companies have started to further invest in DNA fragmentation- and methylation-based platforms to detect a variety of early-stage cancers.